The FDA is raising efficacy questions over Lundbeck and Otsuka’s proposed combination of their Rexulti with Viatris’ Zoloft ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile ...

The FDA cracked down on two plants in India and one in Korea in separate recently released reports, citing issues ranging ...

Nostrum Labs, which declared bankruptcy last year and has since ceased operations, issued a voluntary recall for all lots of ...

Consumers are now almost as likely to say they learn about new medications from advertisements on linear or connected TV as ...

Illustrating its confidence in its proprietary products, the Southern California company has announced an ambitious plan to ...

Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications. | ...

Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Real Chemistry has made a flurry of leadership appointments, including hiring JJ Schmuckler from VML to fill a newly created role while also making changes at 21Grams and its communications group.

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...